iC9-CAR19 cells
Phase 2Cell therapy
iC9-CAR19 cells is one of 85 biologic programs targeting Lymphoma. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
iC9-CAR19 cells
UUNC Lineberger Comprehensive Cancer Center
Phase 2
Nuvigil
NNuvo Research GmbH
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory1 trial
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT03016377·17 enrolled
T Cells1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iC9-CAR19 cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details